167
Participants
Start Date
March 4, 2019
Primary Completion Date
January 9, 2020
Study Completion Date
January 16, 2020
50 mcg Duramorph+ EXPAREL + multi-modal pain regimen
Intrathecal injection of 50 mcg Duramorph + EXPAREL administered via TAP infiltration + multi-modal pain regimen.
150 mcg Duramorph + multi-modal pain regimen
Intrathecal injection of 150 mcg Duramorph + multi-modal pain regimen.
Exparel TAP + multi-modal pain regimen
EXPAREL administered via TAP infiltration + multi-modal pain regimen.
Columbia University Medical Center/NY Presbyterian Hospital, New York
Magee-Women's Hospital of UPMC, Pittsburgh
Thomas Jefferson Medical Center, Philadelphia
Inova Health System, Falls Church
Duke University Medical Center, Durham
University of Florida college of Medicine - Jacksonville, Jacksonville
University of Florida- Gainesville, Gainesville
Ohio State University, Columbus
Cleveland Clinic, Cleveland
Henry Ford Hospital, Detroit
Clinical Research Prime, Idaho Falls
West Virginia University, Morgantown
Stanford University School of Medicine, Stanford
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Robert Wood Johnson Medical School, New Brunswick
St. Peter's University Medical Center, New Brunswick
The University of Texas Medical Branch, Galveston
Lead Sponsor
Pacira Pharmaceuticals, Inc
INDUSTRY